ImmunoPrecise Antibodies Ltd. reported earnings results for the third quarter and nine months ended January 31, 2024. For the third quarter, the company reported sales was CAD 6.22 million compared to CAD 5.17 million a year ago. Net loss was CAD 2.94 million compared to CAD 4.7 million a year ago. Basic loss per share from continuing operations was CAD 0.11 compared to CAD 0.19 a year ago.
For the nine months, sales was CAD 18.06 million compared to CAD 15.04 million a year ago. Net loss was CAD 9.13 million compared to CAD 21.43 million a year ago. Basic loss per share from continuing operations was CAD 0.36 compared to CAD 0.86 a year ago.